Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

ICL670A: preclinical profile.

Nick H, Wong A, Acklin P, Faller B, Jin Y, Lattmann R, Sergejew T, Hauffe S, Thomas H, Schnebli HP.

Adv Exp Med Biol. 2002;509:185-203. No abstract available.

PMID:
12572995
2.

Chelator-induced iron excretion in iron-overloaded marmosets.

Sergejew T, Forgiarini P, Schnebli HP.

Br J Haematol. 2000 Sep;110(4):985-92.

PMID:
11054093
3.

4-

Heinz U, Hegetschweiler K, Acklin P, Faller B, Lattmann R, Schnebli HP.

Angew Chem Int Ed Engl. 1999 Sep;38(17):2568-2570.

PMID:
10508341
4.

Selective oxidation of methionyl residues in the human recombinant secretory leukocyte proteinase inhibitor. Effect on the inhibitor binding properties.

Tomova S, Cutruzzolà F, Barra D, Amiconi G, Ascenzi P, Djinović Carugo K, Menegatti E, Sarti P, Schnebli HP, Bolognesi M.

J Mol Recognit. 1994 Mar;7(1):31-7.

PMID:
7986566
5.

Future of oral iron chelator deferiprone (L1)

Pfannkuch F, Bentley P, Schnebli HP.

Lancet. 1993 Jun 5;341(8858):1480. No abstract available.

PMID:
8099178
6.

Toxicity of oral iron chelator L1.

Berdoukas V, Bentley P, Frost H, Schnebli HP.

Lancet. 1993 Apr 24;341(8852):1088. No abstract available.

PMID:
8096974
7.

Structure of the proteinase inhibitor eglin c with hydrolysed reactive centre at 2.0 A resolution.

Betzel C, Dauter Z, Genov N, Lamzin V, Navaza J, Schnebli HP, Visanji M, Wilson KS.

FEBS Lett. 1993 Feb 15;317(3):185-8.

8.

Selective oxidation of Met-192 in bovine alpha-chymotrypsin. Effect on catalytic and inhibitor binding properties.

Cutruzzolá F, Ascenzi P, Barra D, Bolognesi M, Menegatti E, Sarti P, Schnebli HP, Tomova S, Amiconi G.

Biochim Biophys Acta. 1993 Feb 13;1161(2-3):201-8.

PMID:
8431470
9.

Crystal and molecular structure of the bovine alpha-chymotrypsin-eglin c complex at 2.0 A resolution.

Frigerio F, Coda A, Pugliese L, Lionetti C, Menegatti E, Amiconi G, Schnebli HP, Ascenzi P, Bolognesi M.

J Mol Biol. 1992 May 5;225(1):107-23.

PMID:
1583684
10.
11.

Binding of the recombinant proteinase inhibitor eglin c from leech Hirudo medicinalis to serine (pro)enzymes: a comparative thermodynamic study.

Ascenzi P, Aducci P, Amiconi G, Ballio A, Guaragna A, Menegatti E, Schnebli HP, Bolognesi M.

J Mol Recognit. 1991 Jul-Dec;4(4):113-9.

PMID:
1799460
12.

Anti-neutrophil elastase defense of the normal human respiratory epithelial surface provided by the secretory leukoprotease inhibitor.

Vogelmeier C, Hubbard RC, Fells GA, Schnebli HP, Thompson RC, Fritz H, Crystal RG.

J Clin Invest. 1991 Feb;87(2):482-8.

13.

Recombinant elastase inhibitors for therapy.

Schnebli HP.

Ann N Y Acad Sci. 1991;624:212-8. No abstract available.

PMID:
1676575
15.

Aerosolization of recombinant SLPI to augment antineutrophil elastase protection of pulmonary epithelium.

Vogelmeier C, Buhl R, Hoyt RF, Wilson E, Fells GA, Hubbard RC, Schnebli HP, Thompson RC, Crystal RG.

J Appl Physiol (1985). 1990 Nov;69(5):1843-8.

PMID:
2272977
16.

X-ray crystal structure of the bovine alpha-chymotrypsin/eglin c complex at 2.6 A resolution.

Bolognesi M, Pugliese L, Gatti G, Frigerio F, Coda A, Antolini L, Schnebli HP, Menegatti E, Amiconi G, Ascenzi P.

J Mol Recognit. 1990 Aug;3(4):163-8.

PMID:
2278733
18.

Polyethylene glycol modification of serpins improves therapeutic potential.

Mast AE, Salvesen G, Brucato FH, Schnebli HP, Pizzo SV.

Biol Chem Hoppe Seyler. 1990 May;371 Suppl:101-9. No abstract available.

PMID:
2400571
19.

Control of exogenous proteinases and their inhibitors at the macrophage cell surface.

Dean RT, Schnebli HP.

Biochim Biophys Acta. 1989 Aug 18;992(2):174-80.

PMID:
2758063
20.

Preliminary crystallographic data on the complex of bovine alpha-chymotrypsin with the recombinant proteinase inhibitor eglin c from Hirudo medicinalis.

Pugliese L, Gatti G, Bolognesi M, Coda A, Menegatti E, Schnebli HP, Ascenzi P, Amiconi G.

J Mol Biol. 1989 Aug 5;208(3):511-3.

PMID:
2795659
21.

Free radicals inactivate human neutrophil elastase and its inhibitors with comparable efficiency.

Dean RT, Nick HP, Schnebli HP.

Biochem Biophys Res Commun. 1989 Mar 15;159(2):821-7.

PMID:
2784675
22.

Fibronectin-cleaving activity in bronchial secretions of patients with cystic fibrosis.

Suter S, Schaad UB, Morgenthaler JJ, Chevallier I, Schnebli HP.

J Infect Dis. 1988 Jul;158(1):89-100.

PMID:
3292666
23.

Development of Eglin c as a drug: pharmacokinetics.

Nick HP, Probst A, Schnebli HP.

Adv Exp Med Biol. 1988;240:83-8. No abstract available.

PMID:
3245507
24.
25.

Kinetic studies on the interaction of eglin c with human leukocyte elastase and cathepsin G.

Braun NJ, Bodmer JL, Virca GD, Metz-Virca G, Maschler R, Bieth JG, Schnebli HP.

Biol Chem Hoppe Seyler. 1987 Apr;368(4):299-308.

PMID:
3649242
26.

Interaction of Eglin c with polymorphonuclear cells: evidence for binding to the cell surface.

Braun NJ, Schnebli HP.

Biol Chem Hoppe Seyler. 1987 Feb;368(2):155-61.

PMID:
3566916
27.

Comparison of specificity of human and horse leucocyte proteinases with synthetic peptide substrates.

Dubin A, Potempa J, Schnebli HP, Koj A.

Folia Histochem Cytobiol. 1986;24(2):157-61.

PMID:
3639831
28.

A brief review of the biochemistry and pharmacology of Eglin c, an elastase inhibitor.

Braun NJ, Schnebli HP.

Eur J Respir Dis Suppl. 1986;146:541-7. Review.

PMID:
3536558
29.

Eglin-c, a polypeptide derived from the medicinal leech, prevents human neutrophil elastase-induced emphysema and bronchial secretory cell metaplasia in the hamster.

Snider GL, Stone PJ, Lucey EC, Breuer R, Calore JD, Seshadri T, Catanese A, Maschler R, Schnebli HP.

Am Rev Respir Dis. 1985 Dec;132(6):1155-61.

PMID:
3907441
30.
31.

Inhibition of horse leucocyte proteinases by eglin, a proteinase inhibitor from leeches.

Potempa J, Dubin A, Seemüller U, Schnebli HP, Koj A.

Biomed Biochim Acta. 1985;44(2):335-9.

PMID:
4004837
32.

Eglin c, a pharmacologically active elastase inhibitor.

Schnebli HP, Seemüller U, Fritz H, Maschler R, Liersch M, Virca GD, Bodmer JL, Snider GL, Lucey EC, Stone PG.

Eur J Respir Dis Suppl. 1985;139:66-70.

PMID:
3862612
33.

Biochemical properties and possible therapeutic role of the elastase inhibitor eglin C.

Schnebli HP, Seemüller U, Fritz H, Maschler R, Liersch M, Bodmer JL, Virca GD, Lucey EC, Stone PG, Snider GL.

Prog Clin Biol Res. 1985;180:287-90. No abstract available.

PMID:
3849804
34.

Plasma proteinase inhibitors.

Bodmer JL, Schnebli HP.

Schweiz Med Wochenschr. 1984 Oct 6;114(40):1359-63.

PMID:
6208604
35.

Similarities between human and rat leukocyte elastase and cathepsin G.

Virca GD, Metz G, Schnebli HP.

Eur J Biochem. 1984 Oct 1;144(1):1-9.

36.

Decreased thiosulfate sulfur transferase (rhodanese) in Leber's hereditary optic atrophy.

Cagianut B, Schnebli HP, Rhyner K, Furrer J.

Klin Wochenschr. 1984 Sep 17;62(18):850-4.

PMID:
6593495
37.

The elastase/alpha 1-proteinase inhibitor balance in the lung. A review.

Virca GD, Schnebli HP.

Schweiz Med Wochenschr. 1984 Jun 23;114(25):895-8. Review.

PMID:
6379867
38.

Cigarette smoke components are not very effective in directly inactivating alpha 1-proteinase inhibitor.

Wyss A, Virca GD, Schnebli HP.

Hoppe Seylers Z Physiol Chem. 1984 Apr;365(4):511-6.

PMID:
6329941
39.

Plasma levels of inhibitor-bound leukocytic elastase in rheumatoid arthritis patients.

Schnebli HP, Christen P, Jochum M, Mallya RK, Pepys MB.

Adv Exp Med Biol. 1984;167:355-62. No abstract available.

PMID:
6608860
40.
41.

The acute-phase response in (NZB X NZW)F1 and MRL/l MICE.

Rordorf C, Schnebli HP, Baltz ML, Tennent GA, Pepys MB.

J Exp Med. 1982 Oct 1;156(4):1268-73.

42.

[Thiosulfate-sulfur transferase deficiency in Leber's hereditary optic atrophy ].

Cagianut B, Schnebli HP, Rhyner K, Furrer W.

Klin Monbl Augenheilkd. 1982 Jul;181(1):32-5. German. No abstract available.

PMID:
6956776
43.

Subunit structure of the rat alpha-macroglobulin proteinase inhibitors.

Nelles LP, Schnebli HP.

Hoppe Seylers Z Physiol Chem. 1982 Jul;363(7):677-82.

PMID:
6182084
44.

Effect of different elastase inhibitors on leukocyte elastase pre-adsorbed to elastin.

Hornebeck W, Schnebli HP.

Hoppe Seylers Z Physiol Chem. 1982 Apr;363(4):455-8.

PMID:
6918355
45.

Are proteinase inhibitors potentially useful in tumor therapy?

Nelles LP, Schnebli HP.

Invasion Metastasis. 1982;2(2):113-24. Review.

PMID:
6203867
46.

Thiosulphate-sulphur transferase (rhodanese) deficiency in Leber's hereditary optic atrophy.

Cagianut B, Rhyner K, Furrier W, Schnebli HP.

Lancet. 1981 Oct 31;2(8253):981-2. No abstract available.

PMID:
6117741
48.

Isolation and characterization of an enkephalin-degrading aminopeptidase from rat brain.

Schnebli HP, Phillipps MA, Barclay RK.

Biochim Biophys Acta. 1979 Jul 11;569(1):89-98.

PMID:
37915
49.

Reaction of lectins with human erythrocytes. IV. Details of adsorption and desorption of ConA.

Schnebli HP, Lustig A, Zulauf M, Winterhalter KH, Joss U.

Exp Cell Res. 1977 Mar 1;105(1):151-7. No abstract available.

PMID:
837992
50.

Eukaryote ribosomes possess a binding site for concanavalin A.

Howard GA, Schnebli HP.

Proc Natl Acad Sci U S A. 1977 Mar;74(3):818-21.

Supplemental Content

Loading ...
Support Center